Buccal swab-based biomarkers for schizophrenia

​

mRNA normalized fold expression from transcript of interest

Invention Summary:

Schizophrenia (SCZ) is a debilitating and chronic brain disorder characterized by symptoms, such as hallucinations, delusions, and disorganized thoughts. Current diagnostic criteria rely solely on behavioral observations and do not account for molecular and clinical neuroscience-based data. Likewise, treatment for SCZ is also based on behavioral symptom management rather than targeting underlying biological mechanisms. This frequently results in poor outcomes and low treatment compliance. In the interest of improving the diagnosis and treatment of SCZ, there is an unmet need for relevant biomarkers from easily collected samples. 

Rutgers researchers have identified levels of a transcript of interest and levels of a protein of interest from patients’ buccal cells, collected by noninvasive cheek swab, may serve as effective SCZ biomarkers. Notably, these biomarkers in buccal cells afford an opportunity for a molecular diagnostic that does not require a blood sample, which is desirable in a patient population that is generally more hesitant to consent to have blood samples taken than the general population. 

Market Applications:

• Buccal cell mRNA and protein as easily collected, novel SCZ biomarkers.  

• Buccal cell kit for SCZ diagnosis and treatment evaluation. 

Advantages:

• Opportunity for introducing molecular evidence to aid in the diagnosis of SCZ. 

• Buccal cell-derived samples are easily collected from patients. 

Publications: Manuscript in review.

Intellectual Property & Development Status: Provisional application filed. Patent pending. Available for licensing and/or research collaboration. For any business development and other collaborative partnerships, contact:  marketingbd@research.rutgers.edu